SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results